Revolution Medicines, Inc. (RVMD) Key Metrics
RVMD valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $38.14B
- Enterprise value
- $37.58B
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- — 10-yr median 61.8
- Price / book
- 15.7 10-yr median 3.1
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 1.40
RVMD key metrics, 2017–2025
Fiscal year ended December 31, 2025 · U.S. dollarsRVMD valuation Price multiples at each fiscal year-end price.
Price / book+186.6%
9.3
2025 · hover or tap a bar for each year
20172025
Free cash flow yield+1.7 pts
−6.0%
2025 · hover or tap a bar for each year
20172025
RVMD returns How much profit the business earns on the capital it uses.
Return on equity−28.7 pts
−58.1%
2025 · hover or tap a bar for each year
20172025
Return on assets−20.1 pts
−46.1%
2025 · hover or tap a bar for each year
20172025
Asset turnover
0.00
2025 · hover or tap a bar for each year
20172025
RVMD per-share figures Results divided by the shares outstanding at year-end.
Revenue per share
$0.00
2025 · hover or tap a bar for each year
20172025
Earnings per share
−$5.95
2025 · hover or tap a bar for each year
20172025
Free cash flow per share
−$4.81
2025 · hover or tap a bar for each year
20172025
Book value per share−36.5%
$8.58
2025 · hover or tap a bar for each year
20172025
Shares outstanding+13.3%
190.1M
2025 · hover or tap a bar for each year
20172025
RVMD financial health Debt, liquidity and how easily interest is covered.
Debt / equity+62.2%
0.10
2025 · hover or tap a bar for each year
20172025
Net debt+$286.5M
−$1.87B
2025 · hover or tap a bar for each year
20172025
Current ratio−49.7%
7.14
2025 · hover or tap a bar for each year
20172025
Interest coverage
-48.8
2025 · hover or tap a bar for each year
20172025
Debt / assets+26.9%
0.07
2025 · hover or tap a bar for each year
20172025
RVMD efficiency & capital use Working capital cycle and where the cash goes.
Days payables outstanding+1,276 days
1,312 days
2025 · hover or tap a bar for each year
20172025
RVMD valuation history
Fiscal year-endToday9-year median
RVMD returns on capital
ROEROICROA
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
RVMD debt vs cash
Total debtCash & short-term investments
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
RVMD cash returned to shareholders
DividendsBuybacksFree cash flow
RVMD price vs earnings per share
Share price at year-endEPS (right axis)
RVMD key metrics
2017–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|
| Valuation | |||||||||
| Market capitalization | $15.14B | $7.34B | $3.25B | $1.92B | $1.83B | $2.64B | — | — | — |
| Enterprise value | $13.28B | $5.18B | $1.48B | $1.34B | $1.32B | $2.23B | — | — | — |
| Price / sales | — | — | 280.2 | 54.3 | 62.4 | 61.3 | — | — | — |
| Price / book | 9.3 | 3.2 | 1.8 | 2.8 | 3.0 | 5.6 | — | — | — |
| EV / sales | — | — | 127.8 | 37.9 | 45.0 | 51.8 | — | — | — |
| Earnings yield | −7.5% | −8.2% | −13.4% | −12.9% | −10.2% | −4.1% | — | — | — |
| Free cash flow yield | −6.0% | −7.7% | −11.0% | −12.2% | −8.4% | −3.9% | — | — | — |
| Shareholder yield (dividends + buybacks) | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Share price at fiscal year-end | $79.65 | $43.74 | $28.68 | $23.82 | $25.17 | $39.59 | — | — | — |
| Per share | |||||||||
| Revenue per share | $0.00 | $0.00 | $0.10 | $0.44 | $0.40 | $0.65 | — | — | — |
| Earnings per share | −$5.95 | −$3.58 | −$3.86 | −$3.08 | −$2.57 | −$1.62 | — | — | — |
| Operating cash flow per share | −$4.72 | −$3.32 | −$3.10 | −$2.78 | −$2.02 | −$1.50 | — | — | — |
| Free cash flow per share | −$4.81 | −$3.38 | −$3.17 | −$2.92 | −$2.11 | −$1.55 | — | — | — |
| Cash per share | $10.65 | $13.65 | $16.38 | $8.00 | $7.93 | $6.62 | — | — | — |
| Book value per share | $8.58 | $13.50 | $16.14 | $8.50 | $8.28 | $7.13 | — | — | — |
| Tangible book value per share | $8.21 | $13.08 | $15.50 | $7.59 | $7.25 | $5.99 | — | — | — |
| Capex per share | $0.08 | $0.06 | $0.07 | $0.13 | $0.09 | $0.04 | — | — | — |
| Debt per share | $0.83 | $0.81 | $0.78 | $0.80 | $0.92 | $0.49 | — | — | — |
| Shares outstanding | 190.1M | 167.7M | 113.1M | 80.6M | 72.8M | 66.6M | — | — | — |
| Change in shares outstanding | +13.3% | +48.2% | +40.3% | +10.7% | +9.3% | — | — | — | — |
| Returns & profitability | |||||||||
| Return on equity (ROE) | −58.1% | −29.3% | −34.8% | −38.6% | −34.7% | −34.5% | −38.3% | −82.6% | −687.0% |
| Return on invested capital (ROIC) | — | −630.0% | −464.7% | −207.6% | −187.1% | −181.2% | −149.1% | −278.9% | — |
| Return on assets (ROA) | −46.1% | −26.0% | −30.4% | −32.1% | −28.7% | −27.5% | −24.4% | −45.0% | −206.5% |
| Return on tangible assets | −49.5% | −24.1% | −21.9% | −33.7% | −28.2% | −22.0% | −33.1% | −45.0% | −206.5% |
| Free cash flow margin | — | — | — | −664.8% | −523.0% | −239.6% | −104.3% | −1.4% | — |
| Financial health | |||||||||
| Total debt | $158.7M | $135.8M | $87.9M | $64.2M | $66.6M | $32.7M | $172,000 | $318,000 | — |
| Cash & short-term investments | $2.03B | $2.29B | $1.85B | $644.9M | $577.1M | $440.7M | $122.8M | $69.6M | $9.1M |
| Net debt | −$1.87B | −$2.15B | −$1.77B | −$580.7M | −$510.4M | −$408.1M | −$122.6M | −$69.3M | −$9.1M |
| Debt / equity | 0.10 | 0.06 | 0.05 | 0.09 | 0.11 | 0.07 | 0.00 | 0.00 | — |
| Debt / assets | 0.07 | 0.05 | 0.04 | 0.08 | 0.09 | 0.06 | 0.00 | 0.00 | — |
| Current ratio | 7.14 | 14.20 | 13.06 | 10.65 | 9.77 | 9.63 | 3.11 | 2.80 | 1.24 |
| Quick ratio | 7.14 | 14.20 | 13.06 | 10.65 | 9.98 | 9.63 | 3.11 | 2.58 | 1.24 |
| Interest coverage | -48.8 | — | — | -26.7 | — | — | -510.6 | -347.7 | -302.2 |
| Working capital | $1.78B | $2.16B | $1.74B | $598.2M | $529.4M | $406.9M | $90.9M | $54.9M | $1.8M |
| Invested capital | −$235.7M | $111.7M | $61.2M | $104.5M | $92.1M | $66.6M | $29.9M | $27.4M | −$4.5M |
| Tangible asset value | $1.56B | $2.19B | $1.75B | $611.8M | $528.1M | $399.1M | $75.9M | $19.0M | $4.5M |
| Net current asset value | $1.35B | $2.03B | $1.64B | $533.4M | $454.4M | $361.4M | $66.0M | $11.5M | −$1.1M |
| Graham net-net per share | $6.85 | $11.90 | $14.30 | $6.47 | $6.04 | $5.30 | — | — | — |
| Capital allocation | |||||||||
| Share buybacks (net) | $0 | $0 | $0 | $0 | $0 | $0 | $45,000 | $131,000 | $0 |
| Capex / revenue | — | — | 66.7% | 30.6% | 22.2% | 6.8% | 5.2% | 7.4% | — |
| Capex / operating cash flow | — | — | — | — | — | — | — | 123.6% | — |
| Capex / depreciation | 0.97 | 0.87 | 0.83 | 1.12 | 0.89 | 0.45 | 0.77 | 0.85 | 1.33 |
| Stock-based compensation / revenue | — | — | 533.4% | 88.2% | 70.5% | 20.7% | 6.3% | 4.2% | — |
| R&D / revenue | — | — | 3,654.1% | 715.3% | 636.1% | 307.7% | 183.4% | 253.3% | — |
| SG&A / revenue | — | — | 680.7% | 114.7% | 103.6% | 49.9% | 24.8% | 46.7% | — |
| Efficiency | |||||||||
| Days sales outstanding | — | — | 93.4 | 54.7 | 76.5 | 64.2 | 58.5 | 132.2 | — |
| Days of inventory on hand | — | — | 0.0 | -9.2 | -24.8 | — | 13.1 | 47.1 | — |
| Days payables outstanding | 1,312.1 | 35.8 | 36.9 | 25.5 | 26.0 | 33.1 | 33.1 | 30.7 | 46.0 |
| Cash conversion cycle (days) | — | — | 56.5 | 20.0 | 25.7 | 31.1 | 38.5 | 148.6 | — |
| Receivables turnover | — | 0.00 | 3.91 | 6.67 | 4.77 | 5.68 | 6.24 | 2.76 | — |
| Payables turnover | 0.28 | 10.19 | 9.90 | 14.31 | 14.02 | 11.02 | 11.03 | 11.90 | 7.93 |
| Inventory turnover | — | — | 411,244,000.00 | — | — | — | 27.82 | 7.74 | — |
| Asset turnover | 0.00 | 0.00 | 0.01 | 0.05 | 0.05 | 0.11 | 0.26 | 0.22 | 0.00 |
| Average receivables | — | $627,000 | $3.0M | $5.3M | $6.2M | $7.6M | $8.0M | $7.3M | — |
| Average payables | $59.5M | $58.1M | $41.5M | $17.7M | $13.3M | $12.0M | $8.3M | $4.3M | $3.4M |
| Average inventory | — | — | $1 | −$6.4M | −$12.7M | — | $3.3M | $6.6M | — |
| Intangibles / total assets | 3.0% | 2.8% | 3.5% | 9.0% | 10.1% | 13.3% | 34.7% | 45.5% | 0.0% |
Computed from RVMD's annual financial statements (latest annual report filed February 25, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
RVMD valuation and financial ratios
Revolution Medicines earned a return on equity of −58.1% in fiscal 2025. It ended the year with $158.7 million of debt and $2.0 billion in cash and short-term investments, a net cash position of $1.9 billion.
See the RVMD income statement, the RVMD chart for price history, or the RVMD stock overview for the latest quote and news.
RVMD key metrics FAQ
What is Revolution Medicines's return on equity?
Revolution Medicines's return on equity (ROE) was −58.1% in fiscal 2025: net income of -$1.1 billion on average shareholders' equity of $1.9 billion.
How much debt does Revolution Medicines have?
Revolution Medicines had total debt of $158.7 million at the end of fiscal 2025, a debt-to-equity ratio of 0.10 and more cash than debt.
What is Revolution Medicines's free cash flow yield?
Revolution Medicines generated -$913.7 million of free cash flow in fiscal 2025, a free cash flow yield of −6.0% on its market value at year-end ($15.1 billion).
What is Revolution Medicines's current ratio?
Revolution Medicines's current ratio was 7.14 at the end of fiscal 2025: current assets were 7.14 times current liabilities.